u/HonestLiving08x · 152d agono track record yet
“full port, mix of call options with varying expirations (referenced leaps and closer-dated positions, screenshot shown but specific strikes/dates not legible in text)”
All in on cancer $SLS
SLS's GPS drug REGAL trial is near completion (78/80 events) and the author expects a positive outcome based on strong Phase 2 CR2 AML data showing 16.3 months vs 5.4 months median overall survival. Author is fully committed to the position, betting the trial success will drive stock sharply higher.
At post $8.97Now $10.72+19.5% since postedas of Oct 19, 11:31 AM ET
1d-15.7%
3d-13.3%
1w-4.3%
1m-10.3%
3m+46.0%
6m—
1y—